ModerateVitamin K antagonist anticoagulants×Combined oral contraceptives (COC), second generation
Updated · Methodology
Mechanism
Acenocoumarol is a vitamin K antagonist: it reduces the formation of the vitamin K-dependent clotting factors II, VII, IX and X (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The acenocoumarol SmPC lists oral contraceptives among the drugs that can reduce its anticoagulant effect but gives no mechanism for them. As general routes of coumarin interactions, it names impaired absorption, inhibition or induction of liver enzymes, mainly CYP2C9, and reduced availability of vitamin K (acenocoumarol SmPC, AEMPS). According to the Spanish SmPC of Microgynon (levonorgestrel/ethinylestradiol), combined oral contraceptives reduce the effect of oral anticoagulants, probably because of an antagonistic effect on some clotting factors. However, they potentiate the effect of acenocoumarol. In women taking them, laboratory tests can show raised prothrombin and factors VII, VIII, IX and X and lowered antithrombin III (levonorgestrel/ethinylestradiol SmPC, AEMPS). So the documents disagree on the direction of the change. The acenocoumarol SmPC says oral contraceptives can reduce its effect, and the Microgynon SmPC says they can potentiate it. The contraceptive itself raises the risk of venous thromboembolism, and epidemiological studies link it to a higher risk of myocardial infarction and stroke (levonorgestrel/ethinylestradiol SmPCs, AEMPS).
Symptoms
The international normalised ratio (INR) can shift either way. According to the acenocoumarol summary of product characteristics (SmPC), oral contraceptives can reduce the effect of acenocoumarol. The INR then falls below the target range, and protection against clots weakens (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the Microgynon SmPC, the effect of acenocoumarol can increase instead (levonorgestrel/ethinylestradiol SmPC, AEMPS). The contraceptive itself raises the risk of thrombosis. Its SmPC lists signs that need urgent medical help: swelling and pain in one leg, sudden breathlessness, sharp chest pain, sudden numbness or weakness of the face, arm or leg, especially on one side, and difficulty speaking (levonorgestrel/ethinylestradiol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, AEMPS).
Management
The combination itself is not contraindicated. However, section 4.3 of the levonorgestrel/ethinylestradiol summaries of product characteristics (SmPCs) rules out a combined hormonal contraceptive in current or past venous thromboembolism, for example deep vein thrombosis or pulmonary embolism. This applies even when current venous thromboembolism is treated with anticoagulants. If such a condition first appears during use, stop the contraceptive at once. So if acenocoumarol is prescribed for venous thromboembolism, the contraceptive is contraindicated (levonorgestrel/ethinylestradiol SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). The same SmPCs contraindicate the contraceptive in current or past arterial thromboembolism, for example myocardial infarction, and in current or past stroke. They also contraindicate it in thrombogenic valvular disease and thrombogenic rhythm disorders. The Microgynon SmPC adds known predisposition to arterial thromboembolism, such as antiphospholipid antibodies (levonorgestrel/ethinylestradiol SmPCs, AEMPS). The indications of acenocoumarol include atrial fibrillation, the period after myocardial infarction, rheumatic mitral valve disease, prosthetic heart valves and antiphospholipid syndrome (acenocoumarol SmPC, AEMPS). The US label contraindicates levonorgestrel/ethinylestradiol in women at high risk of arterial or venous thrombotic disease. Examples include current or past deep vein thrombosis or pulmonary embolism and thrombogenic valvular or rhythm disease of the heart, such as atrial fibrillation (levonorgestrel/ethinylestradiol prescribing information, US Food and Drug Administration, FDA). Acenocoumarol is contraindicated in pregnancy, and women of childbearing potential must use effective contraception during treatment (acenocoumarol SmPC, AEMPS). The acenocoumarol SmPC lists oral contraceptives among the drugs that can reduce its effect. It asks for close and frequent coagulation checks, for example twice a week, when such a drug is added or stopped. A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. Base dose adjustments on the total weekly dose (acenocoumarol SmPCs, AEMPS). The Microgynon SmPC, by contrast, says that combined oral contraceptives potentiate the effect of acenocoumarol, so the international normalised ratio (INR) may shift either way (levonorgestrel/ethinylestradiol SmPC, AEMPS). With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, also give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.5 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.5 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol Aurovitas 4 mg (nº registro 88315), sección 4.5 (2025)– AEMPS, CIMA, nº registro 88315 (Acenocumarol Aurovitas 4 mg comprimidos EFG; texto idéntico en 1 mg, nº 88278), revisión 07/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.9 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.9 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.9
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.2 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.2 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.2
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.6 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.6 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.6
- AEMPS: Ficha técnica: Levonorgestrel/etinilestradiol, Microgynon 0,15 mg/0,03 mg comprimidos (nº registro 52612), sección 4.5 (2022)– AEMPS, CIMA, nº registro 52612 (Microgynon 0,15 mg/0,03 mg comprimidos recubiertos, Bayer Hispania), revisión 12/2022 (texto revisado 10/2022), secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Levonorgestrel/etinilestradiol, Loette 100/20 microgramos comprimidos (nº registro 65067), sección 4.3 (2026)– AEMPS, CIMA, nº registro 65067 (Loette 100/20 microgramos comprimidos recubiertos con película, Wyeth Farma), revisión 07/2026 (texto revisado 11/2023), secciones 4.3, 4.4 y 4.5
- FDA: Levora (levonorgestrel and ethinyl estradiol) prescribing information (2025)– FDA, DailyMed setid 31679b9f-58c9-4bf1-8c2c-f5a216ff4cd3 (Mayne Pharma), revisión 07/2025 (versión 10), Contraindications y Precautions: Drug Interactions